Бен Линч - Грязные гены. «Большая стирка» для вашей ДНК. Как изменить свою наследственность

79. BH4 needed for feel-good chemicals: Coopen A., et al. “Depression and tetrahydrobiopterin: the folate connection,” Journal of Affective Disorders, March-June 1989, https://www.ncbi.nlm.nih.gov/pubmed/2522108.

80. BH4 needed for feel-good chemicals: Liang, LP., Kaufman, S. “The regulation of dopamine release from striatum slices by tetrahydrobiopterin and L-arginine-derived nitric oxide,” Brain Research, 3 August 1998, https://www.ncbi.nlm.nih.gov/pubmed/9685635.

81. Primary function of NOS3: “NOS3,” Gene Cards, Accessed April 2017, http://www.genecards.org/cgi-bin/carddisp.pl?gene=NOS3&keywords=NOS3.

82. Primary function of NOS3: Loscalzo, Joseph, et al. “Nitric Oxide Insufficiency and Arterial Thrombosis,” Transactions of the American Clinical and Climatological Association, 2000, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194373/pdf/tacca00005-0216.pdf.

83. Effects from a dirty NOS3: Burke, Thomas. “Nitric oxide and its role in health and diabetes,” Diabetes in Control, Accessed April 2017, http://www.diabetesincontrol.com/wp-content/uploads/2015/10/nitric-oxide.pdf.

84. Superoxide leading to diabetic complications: Giacco, Ferdinando, Brownlee, Michael. “Oxidative stress and diabetic complications,” Circulation Research, 29 October 2010, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996922/.

85. Diabetic complications: Katakam, PV., et al. “Insulin-induced generation of reactive oxygen species and uncoupling of nitric oxide synthase underlie the cerebrovascular insulin resistance in obese rats,” Journal of Cerebral Blood Flow and Metabolism, May 2012, https://www.ncbi.nlm.nih.gov/pubmed/22234336.

86. Potential for congenital heart defect: Feng Q., et al. “Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase,” Circulation, 13 August 2002, https://www.ncbi.nlm.nih.gov/pubmed/12176963.

87. Potential for congenital heart defect: Liu Y., et al. “Nitric oxide synthase-3 promotes embryonic development of atrioventricular valves,” PLoS One, 29 October 2013, https://www.ncbi.nlm.nih.gov/pubmed/24204893.

88. Most common birth defect in humans: Liu, Y., Feng, Q. “NOing the heart: role of nitric oxide synthase-3 in heart development,” Differenciation, July 2012, https://www.ncbi.nlm.nih.gov/pubmed/22579300.

89. 400 conditions when NOS3 is dirty: “Genopedia: NOS3,” Center for Disease Control and Prevention, Accessed April 2017, https://phgkb.cdc.gov/HuGENavigator/huGEPedia.do?firstQuery=NOS3&geneID=4846&typeSubmit=GO&check=y&typeOption=gene&which=2&pubOrderType=pubD.

90. 400 conditions when NOS3 is dirty: “NOS3,” Mala Cards, Accessed April 2017, http://www.malacards.org/search/results/NOS3.

91. Erectile Dysfunction: Musicki, B., Burnett, AL. “eNOS function and dysfunction in the penis,” Experimental Biology and Medicine, February 2006, https://www.ncbi.nlm.nih.gov/pubmed/16446491/.

92. Runny nose and high blood pressure: Kirchheimer, Sid. “Sniffing Out High Blood Pressure Risk,” WebMD, 18 February 2003, http://www.webmd.com/hypertension-high-blood-pressure/news/20030218/sniffing-out-high-blood-pressure-risk#1.

93. Effects of dirty NOS3 during pregnancy: Leonardo, DP. et al. “Association of Nitric Oxide Synthase and Matrix Metalloprotease Single Nucleotide Polymorphisms with Preeclampsia and Its Complications,” PLoS One, 28 August 2015, https://www.ncbi.nlm.nih.gov/pubmed/26317342.

94. Heart disease increase after menopause: “Hormone replacement therapy and your heart,” Mayo Clinic, 09 July 2015, http://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-replacement-therapy/art-20047550.

95. Lower estrogen after menopause and increased cardiovascular risk: Hayashi, T. et al. “Effect of Estrogen on Isoforms of Nitric Oxide Synthase: Possible Mechanism of Anti-Atherosclerotic Effect of Estrogen,” Gerontology, 15 April 2009, http://www.karger.com/Article/Abstract/213883.

96. Statins stimulate nitric oxide: Cerda, Alvaro et al. “Role of microRNAs 221/222 on Statin Induced Nitric Oxide Release in Human Endothelial Cells,” Arquivos Brasileiros de Cardiologia, March 2015, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386847/.

97. Side effects of statins: “Side Effects of Cholesterol-Lowering Statin Drugs,” WebMD, Acessed April 2017, http://www.webmd.com/cholesterol-management/side-effects-of-statin-drugs#1.

98. Statins ineffective with dirty NOS3: Hsu, CP. et al. “Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase,” Journal of the American Heart Association, 18 April 2016, https://www.ncbi.nlm.nih.gov/pubmed/27091343.

99. Nitroglycerin resistance: Münzel, T. et al. “Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability,” Circulation Research, 7 January 2000, https://www.ncbi.nlm.nih.gov/pubmed/10625313.

100. Ineffectiveness of nitroglycerin in smokers: Haramaki, N. et al. “Long-term smoking causes nitroglycerin resistance in platelets by depletion of intraplatelet glutathione,” Arteriosclerosis, Thrombosis, and Vascular Biology, November 2001, https://www.ncbi.nlm.nih.gov/pubmed/11701477.

101. Nitroglycerin and arginine with NOS3: Daiber A., Münzel T. “Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress,” Antioxidants & Redox Signaling, 10 October 2015, https://www.ncbi.nlm.nih.gov/pubmed/26261901.

102. Arginine steal: Pernow, J., Jung, C. “Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?” Cardiovascular Research, 1 June 2013, https://www.ncbi.nlm.nih.gov/pubmed/23417041.

103. Bacteria stealing arginine: Cunin, Raymond et al. “Biosynthsis and Metabolism of Arginine in Bacteria,” Microbiological Reviews, September 1986, http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC373073&blobtype=pdf.

104. Arginine ineffective in increasing nitric oxide: Giam, B. et al, “Effects of Dietary l-Arginine on Nitric Oxide Bioavailability in Obese Normotensive and Obese Hypertensive Subjects,” Nutrients, 14 June 2016, https://www.ncbi.nlm.nih.gov/pubmed/27314383.

105. BH4 given to support NOS3: Vásquez-Vivar, J. et al. “Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants,” Arteriosclerosis, Thrombosis, and Vascular Biology, 1 October 2002, https://www.ncbi.nlm.nih.gov/pubmed/12377745.

106. Effectiveness of BH4 given to support NOS3: Mäki-Petäjä, KM. et al. “Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis,” Journal of the American Heart Association, 19 February 2016, https://www.ncbi.nlm.nih.gov/pubmed/26896473.

107. How the body uses arginine: Förstermann, Ulrich, Sessa, William C. “Nitric oxide synthases: regulation and function,” European Heart Journal, April 2012, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345541/.

108. Folic acid increases, level of BH4 decreases: Smith, Desirée E.C. et al. “Folic acid, a double-edged sword? Influence of folic acid on intracellular folate and dihydrofolate reductase activity,” Semantic Scholar, Accessed January 2017, https://pdfs.semanticscholar.org/d934/683d6176b469ff636c4e202b8f99f6bb7217.pdf

109. Sleep apnea and NOS3: Badran, Mohammad et al. “Nitric Oxide Bioavailability in Obstructive Sleep Apnea: Interplay of Asymmetric Dimethylarginine and Free Radicals,” Sleep Disorders, 2015, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438195/.

110. Elevated levels of homocysteine leads to increased levels of ADMA: Selley, ML. “Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease,” Neurobiology of Aging, November 2003, https://www.ncbi.nlm.nih.gov/pubmed/12928048.